Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free NAMSW Stock Alerts

NewAmsterdam Pharma (NAMSW) Competitors

NewAmsterdam Pharma logo
$16.30 0.00 (0.00%)
Closing price 08/25/2026 08:30 AM Eastern
Extended Trading
$16.30 0.00 (0.00%)
As of 08/25/2026 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NAMSW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy NewAmsterdam Pharma stock or one of its competitors? NewAmsterdam Pharma's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NewAmsterdam Pharma compare to Alvotech?

NewAmsterdam Pharma (NASDAQ:NAMSW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Alvotech had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 5 mentions for Alvotech and 1 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.89 beat Alvotech's score of 0.36 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company Overall Sentiment
NewAmsterdam Pharma Very Positive
Alvotech Neutral

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
Alvotech N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

Summary

Alvotech beats NewAmsterdam Pharma on 2 of the 3 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Apollomics?

NewAmsterdam Pharma (NASDAQ:NAMSW) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
Apollomics N/A N/A N/A

In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 1 articles in the media. NewAmsterdam Pharma's average media sentiment score of 1.89 beat Apollomics' score of 1.87 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company Overall Sentiment
NewAmsterdam Pharma Very Positive
Apollomics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

Summary

NewAmsterdam Pharma and Apollomics tied by winning 1 of the 2 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Aravive?

Aravive (NASDAQ:ARAV) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for NewAmsterdam Pharma and 0 mentions for Aravive. NewAmsterdam Pharma's average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
NewAmsterdam Pharma Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Aravive on 3 of the 5 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, bioAffinity Technologies had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 3 mentions for bioAffinity Technologies and 1 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.89 beat bioAffinity Technologies' score of 0.30 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Neutral
NewAmsterdam Pharma Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

Summary

NewAmsterdam Pharma beats bioAffinity Technologies on 2 of the 3 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to BioVie?

BioVie (NASDAQ:BIVIW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

In the previous week, BioVie had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 2 mentions for BioVie and 1 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.89 beat BioVie's score of 0.43 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Neutral
NewAmsterdam Pharma Very Positive

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A

Summary

NewAmsterdam Pharma beats BioVie on 2 of the 3 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAMSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMSW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAMSW vs. The Competition

Export
MetricNewAmsterdam PharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$4.01B$7.24B$12.89B
Dividend YieldN/A3.63%2.54%11.02%
P/E RatioN/A11.83272.5624.24
Price / SalesN/A1,298.90605.1679.37
Price / CashN/A108.3779.8953.65
Price / BookN/A16.6413.096.28
Net IncomeN/A-$22.76M$3.46B$347.85M
7 Day Performance-1.84%3.71%2.17%1.52%
1 Month Performance-21.62%12.07%8.39%4.76%
1 Year Performance18.98%58.71%26.43%17.04%

NewAmsterdam Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAMSW
NewAmsterdam Pharma
N/A$16.30
flat		N/A+19.7%$0.00$7.12MN/A29
ALVOW
Alvotech
N/A$0.49
+63.9%		N/A-67.5%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
+21.5%		N/A-28.4%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.13
+77.1%		N/A+90.0%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NAMSW) was last updated on 8/27/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel